One Hundred Twelfth Congress of the United States of America

AT THE SECOND SESSION

Began and held at the City of Washington on Tuesday, the third day of January, two thousand and twelve

An Act

To make corrections with respect to Food and Drug Administration user fees.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “FDA User Fee Corrections Act of 2012”.

SEC. 2. CORRECTIONS TO FDA USER FEES.


(b) Subchapter C of title VII of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379f et seq.) is amended—

(1) in section 738(i)(2)(A)(ii), by striking “shall only be available” and inserting “shall be available”;

(2) in sections 744B(a)(2)(E)(ii)(II), 744B(a)(3)(C)(ii)(III), 744B(a)(4)(D)(i)(II), and 744B(a)(4)(D)(ii)(II), by inserting “for such year” after “obligation of fees” each place it appears; and

(3) in section 744B(a)(2)(C)—

(A) by inserting a comma after “September 30, 2013”; and

(B) by striking the comma after “for fiscal year 2013”.


(2) Notwithstanding section 744B(a)(3)(C)(ii) of such Act, the fee authorized under section 744B(a)(3) of such Act for fiscal year 2013 shall be due on the later of—

(A) the date of submission of the abbreviated new drug application or prior approval supplement for which such fee applies; or

(B) 30 calendar days after publication of the notice referred to in section 744B(a)(3)(B)(i) of such Act.

(3) Notwithstanding section 744B(a)(4)(D)(i) of such Act, the fee authorized under section 744B(a)(4) of such Act for fiscal year
2013 shall be due not later than 45 days after the publication of the notice under section 744B(a)(4)(C)(i) of such Act.

Speaker of the House of Representatives.

Vice President of the United States and President of the Senate.